Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential treatment strategy with abatacept in ACPA-positive rheumatoid arthritis
2022-500234-29-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Nov 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Remission during 36 weeks by DAS28-CRP. Planned start Nov 2022; status: authorised.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-500234-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500234-29-00.